1. Human Aging ResearchPasswater, Richard A. and Welker, Paul A.Amer. Lab.
3(5):21-6 (May 1971)
2. Pharmokinetics of oral acetylcysteine.Rodenstein, D., DeCoster, A. and
Gazzaniga, A.Clin. Pharmacokin. 3:247-54 (1978)
3. Toxicological, pharmacokinetics and metabolic studies onacetylcysteine.Bonanomi,
L. and Gazzaniga, A.Eur. J. Respir. Dis. 61(Sup):45-51 (1980)
4. Clinical pharmacokinetics of N-acetylcysteine.Borgstrom, L., Kagedal,
B. and Paulsen, O.Eur. J. Clin. Pharmacol. 31:217-22 (1986)
5. Pharmokinetics and bioavailability of reduced and oxidizedN-acetylcysteine.Olsson,
B., et al.Eur. J. Clin. Pharmocol. 34:77-82 (1988)
6. Acetylcysteine: A drug that is much more than a mucokinetic.Ziment, I.Biomed.
Pharmacother. 42:513-20 (1988)
7. Pharmacokinetics and bioavailability of oral acetylcysteinein healthy
volunteers.De Caro, L., et al.Arzneim.-Forsch/Drug Res., 39:382 (1989)
8. Suppression of Cytokine-induced Human Immunodeficiency Virus(HIV) expression
by N-acetylcysteine (NAC), glutathione(GSH) and Glutathione monoester (GSE)Kinter,
Audrey L., et al.75th Annual Meeting of the Federation of American Societiesfor
Experimental Biology, Atlanta, Georgia (April 21-5, 1991)J. FASEB 5(5) A1265
(1991)
9. Suppression of human immunodeficiency virus expression inchronically
infected monocytic cells by glutathione,glutathione ester, and N-acetylcysteine.
Kalebic, Thea, et al.Proc. Natl. Acad. Sci. 88(3):986-90 (1991)
10. Thiol-based compounds may limit AIDS progression.CDC AIDS Weekly p3
(Feb. 25, 1991)
11. Cytokine-stimulated human immunodeficiency virus replicationis inhibited
by N-acetylcysteine.Roederer, M., et al.Proc. Natl. Acad. Sci. 87:4884-8
(1990)
12. Reducing agents and AIDS - Why are we waiting?Turner, V. F.Med. J. Aust.
153/8, 502 (1990)
13. Mercaptoethanol and N-acetylcysteine enhance T-cell colonyformation
in AIDS and ARC. Wu, J., et al.Clin. Exp. Immunol. 77/1, 7-10 (1989)
14. AIDS - Drug therapy; Acetylcysteine research.Cooper, MikeCDC AIDS Weekly
p4 (Oct. 2, 1989)
15. Glutathione deficiency and radiosensitivity in AIDSpatients.Vallis,
K. A.The Lancet 337:918-9 (April 13, 1991)
16. Lipoprotein(a) reduction by N-acetylcysteine.Gavish, Dov and Breslow,
Jan L.The Lancet 337:203-4 (Jan. 26, 1991)
17. N-acetylcysteine and lipoprotein.Stalenhoef, A. F. H., et al.The Lancet
337:491 (1991)
18. AcetylcysteineEditorialThe Lancet 337(8749):1069-70 (May 4, 1991)
19. N-Acetylcysteine and immunoreactivity of lipoprotein(a).Scanu, Angelo
M.The Lancet 337:1159 (May 4, 1991)
20. Metabolic disorder as early consequence of SimianImmunodeficiency Virus
infection in Rhesus macaques.Eck, Hans-Peter, et al.Lancet 338:346-7 (Aug.
10, 1991)
21. Mercaptoethanol and N-acetylcysteine enhance T-cell colonyformation
in AIDS and ARC.Wu, J., Levy, E. M. and Black, P. H.Clin. Exp. Immunol.
77:7-10 (1989)
22. Clinical application for heavy metal-complexing potential ofN-acetylcysteine.Lorber,
A., et al.J. Clin. Pharmacol. 13:332-6 (1973)
23. Treatment of acute methylmercury ingestion byhemodialysis with N-acetylcysteine.Lund,
M. E., Clarkson, T. W. and Berlin, M.J. Toxicol. Clin. Toxicol. 22:31-49
(1984)